http://www.wsw.com/webcast/cc/bmicy2/
At the start of the Q&A session at the 1:40:00 mark you hear that after the PTSD trial they may make a case to the FDA that a GAD trial would be worth running. The PTSD trial is designed to also show affect on other indications, not powered enough to show cause, but enough to show that a further GAD or Depression trial could be warranted. Sounds like a clever trial design, but I think you can't expect too much power out of this 193 participant trial, for all the things they are measuring. I suspect Bionomics will withhold data on some of the secondary measures, ones that don't show enough affect. Not that they are trying to hide anything, it's just that the PTSD trial isn't large enough and run long enough to show an affect on everything, and it's not necessary for PTSD specifically.
A future GAD or Depression trial could then be designed to be powered more correctly based on what is seen with this trial.
Lot of blue sky for Bionomics if this PTSD trial goes well.
BNO Price at posting:
59.5¢ Sentiment: Buy Disclosure: Held
